This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Alcon (ALC) Receives a Hold from Barclays
Barclays analyst Matt Miksic maintained a Hold rating on Alcon yesterday and set a price target of $90.00. The company’s shares closed yesterday at CHF66.76.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Miksic is a 4-star analyst with an average return of 5.1% and a 55.25% success rate. Miksic covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Abbott Laboratories, and Alphatec Holdings.
In addition to Barclays, Alcon also received a Hold from William Blair’s Steven Lichtman in a report issued yesterday. However, on the same day, Wells Fargo upgraded Alcon (NYSE: ALC) to a Buy.
ALC market cap is currently CHF32.11B and has a P/E ratio of 38.94.
Read More on ALC:
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
